About Angiopoietin-related protein 1
Angiopoietin-related protein 1 (ANGPTL1) is a protein
from Homo sapiens identified by UniProt accession
O95841, 491 residues long.
MolForge cross-references it against 0 known binders and
136 disease associations.
Target properties
| Protein name | Angiopoietin-related protein 1 |
| UniProt accession | O95841 |
| Gene | ANGPTL1 |
| Organism | Homo sapiens |
| Length | 491 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (136)
Diseases linked to this target (Open Targets).
- vital capacity · score 0.29
- cortical surface area measurement · score 0.25
- blood protein measurement · score 0.25
- cortical thickness · score 0.25
- brain measurement · score 0.25
- forced expiratory volume · score 0.23
- grip strength measurement · score 0.21
- neuroimaging measurement · score 0.20
- pulse pressure measurement · score 0.17
- body height · score 0.10
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O95841-F1 | alphafold | PREDICTED | 77.65 | — |
Amino-acid sequence (491 residues)
MKTFTWTLGV LFFLLVDTGH CRGGQFKIKK INQRRYPRAT DGKEEAKKCA YTFLVPEQRI TGPICVNTKG QDASTIKDMI TRMDLENLKD VLSRQKREID VLQLVVDVDG NIVNEVKLLR KESRNMNSRV TQLYMQLLHE IIRKRDNSLE LSQLENKILN VTTEMLKMAT RYRELEVKYA SLTDLVNNQS VMITLLEEQC LRIFSRQDTH VSPPLVQVVP QHIPNSQQYT PGLLGGNEIQ RDPGYPRDLM PPPDLATSPT KSPFKIPPVT FINEGPFKDC QQAKEAGHSV SGIYMIKPEN SNGPMQLWCE NSLDPGGWTV IQKRTDGSVN FFRNWENYKK GFGNIDGEYW LGLENIYMLS NQDNYKLLIE LEDWSDKKVY AEYSSFRLEP ESEFYRLRLG TYQGNAGDSM MWHNGKQFTT LDRDKDMYAG NCAHFHKGGW WYNACAHSNL NGVWYRGGHY RSKHQDGIFW AEYRGGSYSL RAVQMMIKPI D
Explore Angiopoietin-related protein 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets